Application 078158
- Type
- ANDA
- Sponsor
- HOSPIRA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | FOSPHENYTOIN SODIUM | FOSPHENYTOIN SODIUM | INJECTABLE;INJECTION | EQ 50MG PHENYTOIN NA/ML | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A078158-001 | FOSPHENYTOIN SODIUM | FOSPHENYTOIN SODIUM | EQ 50MG PHENYTOIN NA/ML | INJECTABLE / INJECTION | 2007-08-06 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A078158-001 | FOSPHENYTOIN SODIUM | EQ 50MG PHENYTOIN NA/ML | INJECTABLE / INJECTION | 2007-08-06 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Fosphenytoin sodium | FOSPHENYTOIN SODIUM | GLENMARK PHARMACEUTICALS INC., USA | a0def32c-e693-43e5-9509-0cef9642441c | 2026-02-18 | Boxed warning, Warnings, Adverse reactions | Fosphenytoin sodium FOSPHENYTOIN SODIUM |
| Fosphenytoin sodium | FOSPHENYTOIN SODIUM | GLENMARK PHARMACEUTICALS INC., USA | bb38bc6a-99c7-4cda-b3f0-37f629d060cf | 2026-02-18 | Boxed warning, Warnings, Adverse reactions | Fosphenytoin sodium FOSPHENYTOIN SODIUM |
| CEREBYX | FOSPHENYTOIN SODIUM | Pfizer Laboratories Div Pfizer Inc | d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a | 2025-08-28 | Boxed warning, Warnings, Adverse reactions | FOSPHENYTOIN SODIUM |
| CEREBYX | FOSPHENYTOIN SODIUM | Pfizer Laboratories Div Pfizer Inc | de5a6711-4abb-4c3d-a18b-266b094ace11 | 2025-05-18 | Boxed warning, Warnings, Adverse reactions | FOSPHENYTOIN SODIUM |
| Fosphenytoin Sodium | FOSPHENYTOIN SODIUM | Sagent Pharmaceuticals | e1dab8ad-cbf6-4273-92fa-02629de2abde | 2024-12-18 | Boxed warning, Warnings, Adverse reactions | Fosphenytoin Sodium FOSPHENYTOIN SODIUM |
| Fosphenytoin Sodium | FOSPHENYTOIN SODIUM | Amneal Pharmaceuticals LLC | 87ff8a91-5b37-401c-b75c-dc6efd348761 | 2024-10-25 | Warnings, Adverse reactions | Fosphenytoin Sodium FOSPHENYTOIN SODIUM |
| Fosphenytoin Sodium | FOSPHENYTOIN SODIUM | Hikma Pharmaceuticals USA Inc. | 519a44e3-8a93-456c-b71c-894513810d45 | 2024-04-10 | Boxed warning, Warnings, Adverse reactions | Fosphenytoin Sodium FOSPHENYTOIN SODIUM |
| Fosphenytoin sodium | FOSPHENYTOIN SODIUM | Gland Pharma Limited | 49b08648-6a83-42c7-ae7b-80c29f2534fc | 2023-10-17 | Boxed warning, Warnings, Adverse reactions | Fosphenytoin sodium FOSPHENYTOIN SODIUM |
| Fosphenytoin | FOSPHENYTOIN SODIUM | Fresenius Kabi USA, LLC | b60c9c82-e5c7-4e05-98c7-5bbba4af04b2 | 2023-03-31 | Boxed warning, Warnings, Adverse reactions | FOSPHENYTOIN SODIUM |
| Fosphenytoin Sodium | FOSPHENYTOIN SODIUM | West-Ward Pharmaceuticals Corp | c92df63b-5140-4213-8d43-8327ff6230b7 | 2018-01-04 | Boxed warning, Warnings, Adverse reactions | Fosphenytoin Sodium FOSPHENYTOIN SODIUM |